Aardvark Therapeutics, Inc. (AARD) Ownership
AARD ownership summary
as of October 18, 2026- Institutions
- 52.6% of shares outstanding
- Insiders
- 15.77% of shares outstanding
- Shares outstanding
- 21.9M
- Float
- 11.0M shares available to trade
- Short interest
- 3.24% 474K shares short
- Days to cover
- 3.93 short interest up 11.6% vs prior month
- Institutions 52.60%
- Insiders 15.77%
- Other investors 31.63%
AARD top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Decheng Capital LLC | 17.90% | 3.9M | $14.8M | — | June 30, 2026 |
| 2 | Citadel Advisors Llc | 5.86% | 1.3M | $4.9M | +40,389 (+3.2%) | June 30, 2026 |
| 3 | LAURION CAPITAL MANAGEMENT LP | 4.73% | 1.0M | $3.9M | — | June 30, 2026 |
| 4 | Vanguard Capital Management, LLC | 2.57% | 563K | $2.1M | +8,776 (+1.6%) | June 30, 2026 |
| 5 | AQR Capital Management LLC | 2.19% | 480K | $1.8M | +345,754 (+257.1%) | June 30, 2026 |
| 6 | EcoR1 Capital, LLC | 1.81% | 396K | $1.5M | +396,194 (0.0%) | June 30, 2026 |
| 7 | Adage Capital Partners Gp LLC | 1.37% | 300K | $1.1M | — | June 30, 2026 |
| 8 | CANTOR FITZGERALD, L. P. | 1.07% | 233K | $881,360 | +166,482 (+249.7%) | June 30, 2026 |
| 9 | BlackRock Inc | 0.85% | 187K | $707,030 | −605,526 (−76.4%) | June 30, 2026 |
| 10 | Geode Capital Management, LLC | 0.68% | 150K | $566,410 | −159,605 (−51.6%) | June 30, 2026 |
| 11 | Two Sigma Investments LLC | 0.50% | 108K | $409,665 | −54,978 (−33.7%) | June 30, 2026 |
| 12 | Vanguard Fiduciary Trust Co | 0.34% | 75K | $284,150 | −8,038 (−9.7%) | June 30, 2026 |
| 13 | Woodline Partners LP | 0.33% | 72K | $273,782 | — | June 30, 2026 |
| 14 | Millennium Management LLC | 0.32% | 70K | $264,403 | −28,386 (−28.9%) | June 30, 2026 |
| 15 | State Street Corp | 0.27% | 59K | $224,052 | −140,049 (−70.3%) | June 30, 2026 |
| 16 | J. Goldman & Co LP | 0.19% | 40K | $153,090 | +40,500 (0.0%) | June 30, 2026 |
| 17 | IEQ CAPITAL, LLC | 0.18% | 38K | $145,084 | +21,897 (+132.8%) | June 30, 2026 |
| 18 | UBS Group AG | 0.16% | 36K | $134,715 | −122,249 (−77.4%) | June 30, 2026 |
| 19 | Morgan Stanley - Brokerage Accounts | 0.14% | 30K | $114,069 | +12,615 (+71.8%) | June 30, 2026 |
| 20 | Northern Trust Corp | 0.13% | 28K | $106,142 | −60,519 (−68.3%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 8 holders added 1.0M shares and 8 cut 1.2M.
AARD top mutual fund and ETF holders
19 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 1.87% | 409K | $1.5M | — | August 31, 2026 |
| 2 | A4Investments SICAV SIF ACCI IlanaA2EURH | 0.87% | 190K | $718,200 | +190,000 (0.0%) | September 30, 2026 |
| 3 | iShares Biotechnology ETF | 0.45% | 98K | $372,043 | −744 (−0.8%) | September 30, 2026 |
| 4 | Fidelity Extended Market Index | 0.31% | 67K | $254,972 | +2,627 (+4.1%) | August 31, 2026 |
| 5 | iShares Micro-Cap ETF | 0.18% | 40K | $152,523 | −278 (−0.7%) | September 30, 2026 |
| 6 | EA Bridgeway Ultra-Small Company Mkt ETF | 0.11% | 24K | $89,533 | — | September 30, 2026 |
| 7 | Fidelity Total Market Index | 0.10% | 23K | $85,553 | — | August 31, 2026 |
| 8 | Fidelity Series Total Market Index | 0.09% | 19K | $70,818 | — | August 31, 2026 |
| 9 | iShares Nasdaq US Biotech ETF USD Acc | 0.07% | 16K | $62,041 | +140 (+0.9%) | September 30, 2026 |
| 10 | Vanguard Balanced Index Inv | 0.04% | 8,867 | $33,517 | — | August 31, 2026 |
| 11 | Fidelity VIP Disciplined Small Cap Init | 0.04% | 7,980 | $30,164 | — | July 31, 2026 |
| 12 | Vanguard U.S. Eq Idx £ Acc | 0.03% | 5,893 | $22,276 | — | August 31, 2026 |
| 13 | Avantis US Small Cap Equity ETF | 0.02% | 4,529 | $17,120 | +256 (+6.0%) | September 30, 2026 |
| 14 | China Universal NASDAQ Bio-Tch ETF(QDII) | 0.02% | 3,472 | $13,124 | −76 (−2.1%) | June 30, 2026 |
| 15 | 1290 VT Micro Cap K | 0.01% | 2,768 | $10,463 | — | August 31, 2026 |
| 16 | Invesco Nasdaq Biotechnology ETF | 0.01% | 1,525 | $5,764 | +70 (+4.8%) | September 30, 2026 |
| 17 | AQR Small Cap Multi-Style I | 0.01% | 1,503 | $5,681 | +1,503 (0.0%) | June 30, 2026 |
| 18 | DFA US Micro Cap I | 0.01% | 1,222 | $4,619 | +1,222 (0.0%) | August 31, 2026 |
| 19 | Fidelity Nasdaq Composite Index | <0.01% | 981 | $3,708 | −14,502 (−93.7%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
AARD insider transactions
latest 7| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-11 | Nelson Sun | Buy | $14.40 | 3,000 | $43,200 |
| 2025-12-11 | Tien-Li Lee | Buy | $14.48 | 7,000 | $101,360 |
| 2025-09-15 | Tien-Li Lee | Buy | $9.66 | 10,000 | $96,600 |
| 2025-09-12 | Tien-Li Lee | Buy | $8.50 | 5,000 | $42,500 |
| 2025-09-11 | Tien-Li Lee | Buy | $7.82 | 6,000 | $46,920 |
| 2025-09-10 | Tien-Li Lee | Buy | $7.91 | 9,000 | $71,190 |
| 2025-09-09 | Nelson Sun | Buy | $8.07 | 6,000 | $48,420 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
AARD shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns AARD
Institutional investors own 52.6% of Aardvark Therapeutics's shares and insiders 15.77%. The largest holder is Decheng Capital LLC with 17.90% of the shares (3.9M), as of June 30, 2026. Among the top 20 institutions, 8 added shares and 8 reduced their stake in the latest filings. Short interest is 3.24% of the float, or 3.93 days of average trading volume. The share count rose 445.4% since 2022.
Related: AARD analyst forecast, AARD key metrics. See the AARD stock overview for the latest quote and news.
AARD ownership FAQ
Who owns the most Aardvark Therapeutics stock?
The largest shareholders of Aardvark Therapeutics are Decheng Capital LLC (17.90%), Citadel Advisors Llc (5.86%), LAURION CAPITAL MANAGEMENT LP (4.73%), Vanguard Capital Management, LLC (2.57%), AQR Capital Management LLC (2.19%).
What percentage of Aardvark Therapeutics is owned by institutions?
Institutions hold 52.6% of Aardvark Therapeutics's shares outstanding; insiders hold 15.77%.
Which funds own Aardvark Therapeutics?
The largest fund holders of Aardvark Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (1.87%), A4Investments SICAV SIF ACCI IlanaA2EURH (0.87%), iShares Biotechnology ETF (0.45%), Fidelity Extended Market Index (0.31%), iShares Micro-Cap ETF (0.18%).
What is Aardvark Therapeutics's short interest?
474K shares of Aardvark Therapeutics were sold short, 3.24% of the float; at the average daily volume it would take 3.93 days to cover.
Are insiders buying or selling Aardvark Therapeutics?
Of the latest 7 reported insider transactions in Aardvark Therapeutics (since September 9, 2025), 7 were purchases and 0 were sales.
How many shares of Aardvark Therapeutics are outstanding?
Aardvark Therapeutics has 21.9M shares outstanding, of which 11.0M are in the public float.